FDA Approved: SUSVIMO — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SUSVIMO, a port delivery system delivering ranibizumab, for treatment of wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• SUSVIMO (Ranibizumab)

Snippet

SUPPL AP for SUSVIMO (RANIBIZUMAB)